Noninvasive imaging of myocardial extracellular matrix for assessment of fibrosis

Current Opinion in Cardiology

Volumn 28, Issue 3, 2013, Pages 282-289

  Won, Samuel ^a,b   Davies Venn, Cynthia ^a,b   Liu, Songtao ^a,b   Bluemke, David A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

extracellular matrix; imaging; left ventricular remodeling; magnetic resonance; myocardial fibrosis

Indexed keywords

ARGININE GLYCINE ASPARTIC ACID; BIOLOGICAL MARKER; COLLAGELIN; COLLAGEN; EP 3533; GADOLINIUM PENTETATE MEGLUMINE; INDIUM 111; INTEGRIN; KR31173 C 11; LISINOPRIL TC 99M; LOSARTAN TC 99M; MATRIX METALLOPROTEINASE; PEPTIDE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RP805 TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANGIOGENESIS; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CORRELATIONAL STUDY; CROSS LINKING; DIAGNOSTIC ACCURACY; DISEASE COURSE; EARLY DIAGNOSIS; EPICARDIUM MAPPING; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RADIODIAGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOMYOPATHIES; EXTRACELLULAR MATRIX; FIBROSIS; HEART; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84876293435     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835f5a2b     Document Type: Review

References (73)

1. Elnakish MT, Kuppusamy P, Khan M. Stem cell transplantation as a therapy for cardiac fibrosis. J Pathol 2012; 229:347-354.
2. de Haas HJ, van den Borne SW, Boersma HH, et al. Evolving role of molecular imaging for new understanding: targeting myofibroblasts to predict remodeling. Ann New York Acad Sci 2012; 1254:33-41.
3. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006; 48:1977-1985.
4. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation 2006; 113:2733-2743.
5. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008; 118:1011-1020.
6. Leyva F, Taylor R, Foley PW, et al. Left Ventricular Midwall Fibrosis as a Predictor of Mortality and Morbidity After Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy. J Am Coll Cardiol 2012; 60:1659-1667.
7. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 2000; 15:290-301.
8. Spach MS, Boineau JP. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. Pacing Clin Electrophysiol 1997; 20 (2 Pt 2):397-413.
9. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994; 89:151-163.
10. Chaturvedi RR, Herron T, Simmons R, et al. Passive stiffness of myocardium from congenital heart disease and implications for diastole. Circulation 2010; 121:979-988.
11. Ling LH, Kistler PM, Ellims AH, et al. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol 2012; 60:2402-2408.
12. Volders PG, Willems IE, Cleutjens JP, et al. Interstitial collagen is increased in the noninfarcted human myocardium after myocardial infarction. J Mol Cell Cardiol 1993; 25:1317-1323.
13. Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointestinal Liver Physiol 2011; 301:G950-G955.
14. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010; 48:504-511.
15. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003; 200:500-503.
16. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regula-tion of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3:349-363.
17. Brilla CG, Zhou G, Rupp H, et al. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol 1995; 76:8D-13D.
18. Koyama H, Raines EW, Bornfeldt KE, et al. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996; 87:1069-1078.
19. Carragher NO, Levkau B, Ross R, Raines EW. Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin, and talin. J Cell Biol 1999; 147:619-630.
20. Weber KT, Janicki JS, Shroff SG, et al. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988; 62:757-765.
21. Panizo A, Pardo J, Hernandez M, et al. Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. Am J Hypertens 1995; 8:815-822.
22. Alberts B. Molecular biology of the cell. New York: Garland Publishing Co; 1994.
23. Adam O, Theobald K, Lavall D, et al. Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation. J Mol Cell Cardiol 2011; 50:678-685.
24. Robins SP. Biochemistry and functional significance of collagen cross-linking. Biochem Soc Trans 2007; 35 (Pt 5):849-852.
25. Naresh NK, Ben-Mordechai T, Leor J, Epstein FH. Molecular imaging of healing after myocardial infarction. Curr Cardiovasc Imaging Rep 2011; 4:63-76.
26. White SK, Sado DM, Flett AS, Moon JC. Characterising the myocardial interstitial space: the clinical relevance of noninvasive imaging. Heart 2012; 98:773-779.
27. Mewton N, Liu CY, Croisille P, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011; 57:891-903.
28. Nacif MS, Turkbey EB, Gai N, et al. Myocardial T1 mapping with MRI: comparison of look-locker and MOLLI sequences. J Magn Reson Imaging 2011; 34:1367-1373.
29. Robbers LF, Baars EN, Brouwer WP, et al. T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. Circ Cardiovasc Imaging 2012; 5:423-426.
30. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology 2001; 218:703-710.
31. Jerosch-Herold M, Sheridan DC, Kushner JD, et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2008; 295:H1234-H1242.
32. Sado DM, Flett AS, Moon JC. Novel imaging techniques for diffuse myocardial fibrosis. Future Cardiol 2011; 7:643-650.
33. Kellman P, Wilson JR, Xue H, et al. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. J Cardiovasc Magn Reson 2012; 14:64.
34. Kellman P, Wilson JR, Xue H, et al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson 2012; 14:63.
35. Ugander M, Kanski M, Engblom H, et al. Pulmonary blood volume variation decreases after myocardial infarction in pigs: a quantitative and noninvasive MR imaging measure of heart failure. Radiology 2010; 256:415-423.
36. Ugander M, Oki AJ, Hsu LY, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 2012; 33:1268-1278.
37. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 2012; 126:1206-1216.
38. Liu S, Han J, Nacif MS, et al. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials. J Cardiovasc Magn Reson 2012; 14:90.
39. Nacif MS, Kawel N, Lee JJ, et al. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology 2012; 264:876-883.
40. Kawel N, Nacif M, Zavodni A, et al. T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson 2012; 14:27.
41. Su H, Spinale FG, Dobrucki LW, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005; 112:3157-3167.
42. Liu YH, Sahul Z, Weyman CA, et al. Accuracy and reproducibility of absolute quantification of myocardial focal tracer uptake from molecularly targeted SPECT/CT: a canine validation. Soc Nuclear Med 2011; 52:453-460.
43. Sahul ZH, Mukherjee R, Song J, et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardio-vasc Imaging 2011; 4:381-391.
44. Higuchi T, Bengel FM, Seidl S, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res 2008; 78:395-403.
45. van den Borne SW, Isobe S, Verjans JW, et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol 2008; 52:2017-2028.
46. van den Borne SW, Isobe S, Zandbergen HR, et al. Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC Cardiovasc Imaging 2009; 2:187-198.
47. Verjans J, Wolters S, Laufer W, et al. Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging. J Nuclear Cardiol 2010; 17:1065-1072.
48. Sherif HM, Saraste A, Nekolla SG, et al. Molecular imaging of early alphav-beta3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. Soc Nuclear Med 2012; 53:318-323.
49. Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting alpha(v)beta(3) integrin expression, in a patient after acute myocardial infarction. Eur Heart J 2008; 29:2201.
50. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849-1865.
51. Anversa P, Cheng W, Liu Y, et al. Apoptosis and myocardial infarction. Basic Res Cardiol 1998; 93 (Suppl 3):8-12.
52. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992; 86:431-438.
53. Brunner-La Rocca HP, Vaddadi G, Esler MD. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. J Am Coll Cardiol 1999; 33:1163-1173.
54. Dilsizian V, Zynda TK, Petrov A, et al. Molecular imaging of human ACE-1 expression in transgenic rats. JACC Cardiovasc Imaging 2012; 5:409-418.
55. Verjans JW, Lovhaug D, Narula N, et al. Noninvasive imaging of angiotensin receptors after myocardial infarction. JACC Cardiovasc Imaging 2008; 1:354-362.
56. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997; 96:4065-4082.
57. Fukushima K, Bravo PE, Higuchi T, et al. Molecular hybrid positron emission tomography/computed tomography imaging of cardiac angiotensin II type 1 receptors. J Am Coll Cardiol 2012; 60:2527-2534.
58. Caravan P, Das B, Dumas S, et al. Collagen-targeted MRI contrast agent for molecular imaging offibrosis. Angew Chem Int Ed Engl 2007; 46:8171-8173.
59. Caravan P, Das B, Deng Q, et al. A lysine walk to high relaxivity collagen-targeted MRI contrast agents. Chem Commun (Camb) 2009:430-432.
60. Helm PA, Caravan P, French BA, et al. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology 2008; 247:788-796.
61. Zong Y, Xu Y, Liang X, et al. A 'Collagen Hug' model for Staphylococcus aureus CNA binding to collagen. EMBO J 2005; 24:4224-4236.
62. Sanders HM, Strijkers GJ, Mulder WJ, et al. Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes. Contrast Media Mol Imaging 2009; 4:81-88.
63. van Bochove GS, Sanders HMHF, de Smet M, et al. Molecular MR imaging of collagen in mouse atherosclerosis by using paramagnetic CNA35 micelles. Eur J Inorganic Chem 2012; 2012:2115-2125.
64. Rekhter MD. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res 1999; 41:376-384.
65. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003; 10:267-274.
66. Barnes MJ. Collagens in atherosclerosis. Collagen Related Res 1985; 5:65-97.
67. Rodriguez-Feo JA, Sluijter JP, de Kleijn DP, Pasterkamp G. Modulation of collagen turnover in cardiovascular disease. Curr Pharm Des 2005; 11:2501-2514.
68. Klink A, Heynens J, Herranz B, et al. In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol 2011; 58:2522-2530.
69. Muzard J, Sarda-Mantel L, Loyau S, et al. Noninvasive molecular imaging of fibrosis using a collagen-targeted peptidomimetic of the platelet collagen receptor glycoprotein VI. PloS One 2009; 4:e5585.
70. Nahrendorf M, Hu K, Frantz S, et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006; 113:1196-1202.
71. Paye M, Nusgens BV, Lapiere CM. Factor-XIII of blood-coagulation modulates collagen biosynthesis by fibroblasts in vitro. Haemostasis 1989; 19:274-283.
72. Akagi A, Tajima S, Ishibashi A, et al. Type XVI collagen is expressed in factor XIIIa(+) monocyte-derived dermal dendrocytes and constitutes a potential substrate for factor XIIIa. J Invest Dermatol 2002; 118:267-274.
73. Nahrendorf M, Aikawa E, Figueiredo JL, et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 2008; 29:445-454.